Positive results for BG-12?In February, Biogen Idec Biogen Idec, Inc. (NASDAQ: BIIB) is a biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen and San Diego, California-based Idec announced that its multi-center clinical trial showed that BG-12 (oral fumarate fumarate /fu·ma·rate/ (fu´mah-rat) a salt of fumaric acid. fumarate a salt of fumaric acid. ) reduced the number of active brain lesions as seen on MRI 1. (application) MRI - Magnetic Resonance Imaging. 2. MRI - Measurement Requirements and Interface. after six months of treatment, compared with inactive placebo. The details have not yet been made public--so experts in MS research have not The National MS Society supports early treatment. Details at: nationalmssociety.org/ Sourcebook-Early.asp. analyzed an·a·lyze tr.v. an·a·lyzed, an·a·lyz·ing, an·a·lyz·es 1. To examine methodically by separating into parts and studying their interrelations. 2. Chemistry To make a chemical analysis of. 3. or reviewed the data. The phase 2 trial involved about 250 people with relapsing-remitting MS in 10 European countries. A more definitive statement about BG-12 will be posted on the Society's Web site, national mssociety.org, when data have been reviewed. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion